{"entity":{"id":"nct06172036","kind":"trial","name":"Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab","aka":["CAPT-02"],"tldr":"A phase 2 trial of cAPOX (capecitabine, oxaliplatin), fluorouracil (5-FU) and leucovorin (folinic acid) in pancreatic cancer, run by Zhejiang University, not yet recruiting.","summary":"Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab is a phase 2, randomised interventional study registered as NCT06172036 by Zhejiang University, with a registry enrolment figure of 180 participants, started 2024-01-20 and due to reach its primary completion in 2026-01-20. Interventions recorded: irinotecan liposome + oxaliplatin + 5-FU / LV; Adebellizumab. Conditions listed: Neoadjuvant Chemotherapy; Resectable Pancreatic Cancer. Primary outcome: 12-month EFS rate. Pancreatic eligibility wording from the registry: \"V2 version), multidisciplinary and imaging evaluation for patients with resectable pancreatic cancer, resectable defined as: by imaging examination, the criteria of radical resection of tumor is no distant metastasis, the artery (trunk celiac, superior mesenteric artery or common hepatic artery), an\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06172036","url":"https://clinicaltrials.gov/study/NCT06172036"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["resectable-pdac","metastatic-pdac"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["capox","fluorouracil","leucovorin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06172036","phase":"2","setting":"A Multicenter, Multi-cohort, Randomized, Phase II Study of Irinotecan Liposome Combined With 5-FU / LV and Oxaliplatin for Resectable Pancreatic Cancer With or Without Addebelizumab","sponsor":"Zhejiang University","enrolled":180,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06172036/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"},{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/"},{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/"},{"id":"leucovorin","kind":"drug","name":"Leucovorin (folinic acid)","route":"/drugs/leucovorin/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}